HAMBURG, Germany, May 5, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) will report its financial results for the first quarter of 2010 on Wednesday, 12 May 2010.
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance:
Conference call details:
| Date: | Wednesday, 12 May 2010 |
|
Time: |
09.30 a.m. CEST 08.30 a.m. BST 03.30 a.m. US time (East Coast) |
|
From Europe: |
+49.(0)69.9897 2631 (Germany) +44.(0)20.7138 0814 (UK) |
| From the US: | +1.718.354 1359 |
| Access Code: | 8395457 |
A simultaneous slide presentation for participants dialing in via phone is available at www.equitystory.com, password: evotec0510.
Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.
A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49.(0)69.2222 2236 (Germany) or +44.(0)20.7111 1244 (UK) and in the US by dialing +1.347.366 9565. The access code is 8395457#. The on-demand version of the webcast will be available on our website: www.evotec.com/Investors/Finance.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information please go to http://www.evotec.com/">www.evotec.com.